Necuparanib, A Multitargeting Heparan Sulfate Mimetic, Targets Tumor and Stromal Compartments in Pancreatic Cancer.
Animals
Antineoplastic Agents
/ administration & dosage
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Gene Expression Regulation, Neoplastic
/ drug effects
Heparitin Sulfate
/ administration & dosage
Humans
Matrix Metalloproteinase 1
/ metabolism
Mice
Neoplasm Invasiveness
Pancreatic Neoplasms
/ drug therapy
Proteomics
/ methods
Spheroids, Cellular
/ cytology
Stromal Cells
/ drug effects
Tissue Inhibitor of Metalloproteinase-3
/ genetics
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
20
04
2018
revised:
06
09
2018
accepted:
02
11
2018
pubmed:
8
11
2018
medline:
26
11
2019
entrez:
8
11
2018
Statut:
ppublish
Résumé
Pancreatic cancer has an abysmal 5-year survival rate of 8%, making it a deadly disease with a need for novel therapies. Here we describe a multitargeting heparin-based mimetic, necuparanib, and its antitumor activity in both
Identifiants
pubmed: 30401693
pii: 1535-7163.MCT-18-0417
doi: 10.1158/1535-7163.MCT-18-0417
doi:
Substances chimiques
Antineoplastic Agents
0
M402 heparan sulfate
0
TIMP3 protein, human
0
Tissue Inhibitor of Metalloproteinase-3
0
Heparitin Sulfate
9050-30-0
MMP1 protein, human
EC 3.4.24.7
Matrix Metalloproteinase 1
EC 3.4.24.7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-256Informations de copyright
©2018 American Association for Cancer Research.